CODX Valuation

Co-Diagnostics Inc

Add to Watchlist

Advanced Chart

0.340

+0.046(15.636%)1D

Overview
Forecast
Valuation
Earnings

CODX Relative Valuation

CODX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CODX is overvalued; if below, it's undervalued.

Historical Valuation

Co-Diagnostics Inc (CODX) is now in the Fair zone, suggesting that its current forward PS ratio of 7.46 is considered Fairly compared with the five-year average of 6.62. The fair price of Co-Diagnostics Inc (CODX) is between 0.30 to 0.86 according to relative valuation methord.

Relative Value

Fair Zone

0.30-0.86

Current Price：0.34

Fair

-0.47

Trailing

Forward

0.00

EV/EBITDA

Co-Diagnostics Inc. (CODX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 5.96. The thresholds are as follows: Strongly Undervalued below -30.23, Undervalued between -30.23 and -12.14, Fairly Valued between 24.05 and -12.14, Overvalued between 24.05 and 42.15, and Strongly Overvalued above 42.15. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.08

EV/EBIT

Co-Diagnostics Inc. (CODX) has a current EV/EBIT of 0.08. The 5-year average EV/EBIT is 3.94. The thresholds are as follows: Strongly Undervalued below -24.64, Undervalued between -24.64 and -10.35, Fairly Valued between 18.23 and -10.35, Overvalued between 18.23 and 32.52, and Strongly Overvalued above 32.52. The current Forward EV/EBIT of 0.08 falls within the Historic Trend Line -Fairly Valued range.

7.46

Co-Diagnostics Inc. (CODX) has a current PS of 7.46. The 5-year average PS is 11.31. The thresholds are as follows: Strongly Undervalued below -12.05, Undervalued between -12.05 and -0.37, Fairly Valued between 22.99 and -0.37, Overvalued between 22.99 and 34.66, and Strongly Overvalued above 34.66. The current Forward PS of 7.46 falls within the Historic Trend Line -Fairly Valued range.

-0.31

P/OCF

Co-Diagnostics Inc. (CODX) has a current P/OCF of -0.31. The 5-year average P/OCF is 2.23. The thresholds are as follows: Strongly Undervalued below -13.62, Undervalued between -13.62 and -5.69, Fairly Valued between 10.15 and -5.69, Overvalued between 10.15 and 18.07, and Strongly Overvalued above 18.07. The current Forward P/OCF of -0.31 falls within the Historic Trend Line -Fairly Valued range.

-0.31

P/FCF

Co-Diagnostics Inc. (CODX) has a current P/FCF of -0.31. The 5-year average P/FCF is -0.10. The thresholds are as follows: Strongly Undervalued below -40.81, Undervalued between -40.81 and -20.45, Fairly Valued between 20.25 and -20.45, Overvalued between 20.25 and 40.60, and Strongly Overvalued above 40.60. The current Forward P/FCF of -0.31 falls within the Historic Trend Line -Fairly Valued range.

Co-Diagnostics Inc (CODX) has a current Price-to-Book (P/B) ratio of 0.21. Compared to its 3-year average P/B ratio of 0.46 , the current P/B ratio is approximately -55.43% higher. Relative to its 5-year average P/B ratio of 1.78, the current P/B ratio is about -88.39% higher. Co-Diagnostics Inc (CODX) has a Forward Free Cash Flow (FCF) yield of approximately -333.60%. Compared to its 3-year average FCF yield of -79.37%, the current FCF yield is approximately 320.28% lower. Relative to its 5-year average FCF yield of -41.48% , the current FCF yield is about 704.19% lower.

0.21

P/B

Median3y

0.46

Median5y

1.78

-333.60

FCF Yield

Median3y

-79.37

Median5y

-41.48

Competitors Valuation Multiple

The average P/S ratio for CODX's competitors is 1.51, providing a benchmark for relative valuation. Co-Diagnostics Inc Corp (CODX) exhibits a P/S ratio of 7.46, which is 393.36% above the industry average. Given its robust revenue growth of -93.87%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Leap Therapeutics Inc

Loss

11.11M

SNSE.O

Sensei Biotherapeutics Inc

Performance Decomposition

Market capitalization of CODX decreased by 78.83% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -286.03 to -4.75K.

The secondary factor is the Revenue Growth, contributed -93.87%to the performance.

Overall, the performance of CODX in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-93.87%

2.66M → 162.91K

Revenue Growth

1558.92%

-286.03 → -4.75K

Margin Expansion

-1543.88%

0.02 → -0.25

P/E Change

-78.83%